B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

Aaron Mansfield, Anja Roden, Tobias D Peikert, Yuri M. Sheinin, Susan M. Harrington, Christopher J. Krco, Haidong M Dong, Eugene D Kwon

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Introduction: B7 homolog 1 (B7-H1; aka programmed cell death 1 ligand 1) is a negative costimulatory molecule that is associated with poor prognosis in many tumor types. Given the poor prognosis and the limited treatments available for mesothelioma, we decided to examine B7-H1 expression and its association with survival in patients with mesothelioma. Methods: Expression of B7-H1 was determined in 106 patients using a mouse monoclonal antihuman B7-H1 (clone 5H1-A3) antibody with immunohistochemistry. Positive expression was defined as 5% positively stained cells. Clinicopathologic features and survival were compared between B7-H1-positive and B7-H1-negative groups. Results: Malignant mesotheliomas of 42 patients (40%) expressed B7-H1. Patients with B7-H1-postive tumors were less likely to be offered or undergo therapeutic surgery (p = 0.03). All sarcomatoid mesotheliomas except one desmoplastic subtype expressed B7-H1. Survival was significantly decreased for patients whose tumors expressed B7-H1 (5 months median, 2-9.5 months interquartile range) compared with those whose tumors did not (14.5 months, 9.25-19 months; p < 0.0001). In a multivariate model, B7-H1 expression and sarcomatoid mesothelioma remained significantly associated with worse survival (risk ratio 1.71, 95% confidence interval 1.03-2.78 [p = 0.04] and risk ratio 2.18, 1.08-4.23 [p = 0.03], respectively). Conclusions: B7-H1 is expressed in a substantial proportion of malignant pleural mesotheliomas and is associated with poor survival. Almost all malignant pleural mesotheliomas with sarcomatoid differentiation expressed B7-H1. The expression of B7-H1 may have important therapeutic implications for the management of malignant pleural mesothelioma.

Original languageEnglish (US)
Pages (from-to)1036-1040
Number of pages5
JournalJournal of Thoracic Oncology
Volume9
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Mesothelioma
Histology
Survival
CD274 Antigen
Neoplasms
Odds Ratio
Therapeutics
Clone Cells
Immunohistochemistry
Malignant Mesothelioma
Confidence Intervals
Antibodies

Keywords

  • B7-H1
  • Immunology
  • Mesothelioma
  • PD-L1
  • Sarcomatoid

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. / Mansfield, Aaron; Roden, Anja; Peikert, Tobias D; Sheinin, Yuri M.; Harrington, Susan M.; Krco, Christopher J.; Dong, Haidong M; Kwon, Eugene D.

In: Journal of Thoracic Oncology, Vol. 9, No. 7, 2014, p. 1036-1040.

Research output: Contribution to journalArticle

@article{3e3b9ef42a5f468a96e0ec1b09be066a,
title = "B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis",
abstract = "Introduction: B7 homolog 1 (B7-H1; aka programmed cell death 1 ligand 1) is a negative costimulatory molecule that is associated with poor prognosis in many tumor types. Given the poor prognosis and the limited treatments available for mesothelioma, we decided to examine B7-H1 expression and its association with survival in patients with mesothelioma. Methods: Expression of B7-H1 was determined in 106 patients using a mouse monoclonal antihuman B7-H1 (clone 5H1-A3) antibody with immunohistochemistry. Positive expression was defined as 5{\%} positively stained cells. Clinicopathologic features and survival were compared between B7-H1-positive and B7-H1-negative groups. Results: Malignant mesotheliomas of 42 patients (40{\%}) expressed B7-H1. Patients with B7-H1-postive tumors were less likely to be offered or undergo therapeutic surgery (p = 0.03). All sarcomatoid mesotheliomas except one desmoplastic subtype expressed B7-H1. Survival was significantly decreased for patients whose tumors expressed B7-H1 (5 months median, 2-9.5 months interquartile range) compared with those whose tumors did not (14.5 months, 9.25-19 months; p < 0.0001). In a multivariate model, B7-H1 expression and sarcomatoid mesothelioma remained significantly associated with worse survival (risk ratio 1.71, 95{\%} confidence interval 1.03-2.78 [p = 0.04] and risk ratio 2.18, 1.08-4.23 [p = 0.03], respectively). Conclusions: B7-H1 is expressed in a substantial proportion of malignant pleural mesotheliomas and is associated with poor survival. Almost all malignant pleural mesotheliomas with sarcomatoid differentiation expressed B7-H1. The expression of B7-H1 may have important therapeutic implications for the management of malignant pleural mesothelioma.",
keywords = "B7-H1, Immunology, Mesothelioma, PD-L1, Sarcomatoid",
author = "Aaron Mansfield and Anja Roden and Peikert, {Tobias D} and Sheinin, {Yuri M.} and Harrington, {Susan M.} and Krco, {Christopher J.} and Dong, {Haidong M} and Kwon, {Eugene D}",
year = "2014",
doi = "10.1097/JTO.0000000000000177",
language = "English (US)",
volume = "9",
pages = "1036--1040",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",

}

TY - JOUR

T1 - B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis

AU - Mansfield, Aaron

AU - Roden, Anja

AU - Peikert, Tobias D

AU - Sheinin, Yuri M.

AU - Harrington, Susan M.

AU - Krco, Christopher J.

AU - Dong, Haidong M

AU - Kwon, Eugene D

PY - 2014

Y1 - 2014

N2 - Introduction: B7 homolog 1 (B7-H1; aka programmed cell death 1 ligand 1) is a negative costimulatory molecule that is associated with poor prognosis in many tumor types. Given the poor prognosis and the limited treatments available for mesothelioma, we decided to examine B7-H1 expression and its association with survival in patients with mesothelioma. Methods: Expression of B7-H1 was determined in 106 patients using a mouse monoclonal antihuman B7-H1 (clone 5H1-A3) antibody with immunohistochemistry. Positive expression was defined as 5% positively stained cells. Clinicopathologic features and survival were compared between B7-H1-positive and B7-H1-negative groups. Results: Malignant mesotheliomas of 42 patients (40%) expressed B7-H1. Patients with B7-H1-postive tumors were less likely to be offered or undergo therapeutic surgery (p = 0.03). All sarcomatoid mesotheliomas except one desmoplastic subtype expressed B7-H1. Survival was significantly decreased for patients whose tumors expressed B7-H1 (5 months median, 2-9.5 months interquartile range) compared with those whose tumors did not (14.5 months, 9.25-19 months; p < 0.0001). In a multivariate model, B7-H1 expression and sarcomatoid mesothelioma remained significantly associated with worse survival (risk ratio 1.71, 95% confidence interval 1.03-2.78 [p = 0.04] and risk ratio 2.18, 1.08-4.23 [p = 0.03], respectively). Conclusions: B7-H1 is expressed in a substantial proportion of malignant pleural mesotheliomas and is associated with poor survival. Almost all malignant pleural mesotheliomas with sarcomatoid differentiation expressed B7-H1. The expression of B7-H1 may have important therapeutic implications for the management of malignant pleural mesothelioma.

AB - Introduction: B7 homolog 1 (B7-H1; aka programmed cell death 1 ligand 1) is a negative costimulatory molecule that is associated with poor prognosis in many tumor types. Given the poor prognosis and the limited treatments available for mesothelioma, we decided to examine B7-H1 expression and its association with survival in patients with mesothelioma. Methods: Expression of B7-H1 was determined in 106 patients using a mouse monoclonal antihuman B7-H1 (clone 5H1-A3) antibody with immunohistochemistry. Positive expression was defined as 5% positively stained cells. Clinicopathologic features and survival were compared between B7-H1-positive and B7-H1-negative groups. Results: Malignant mesotheliomas of 42 patients (40%) expressed B7-H1. Patients with B7-H1-postive tumors were less likely to be offered or undergo therapeutic surgery (p = 0.03). All sarcomatoid mesotheliomas except one desmoplastic subtype expressed B7-H1. Survival was significantly decreased for patients whose tumors expressed B7-H1 (5 months median, 2-9.5 months interquartile range) compared with those whose tumors did not (14.5 months, 9.25-19 months; p < 0.0001). In a multivariate model, B7-H1 expression and sarcomatoid mesothelioma remained significantly associated with worse survival (risk ratio 1.71, 95% confidence interval 1.03-2.78 [p = 0.04] and risk ratio 2.18, 1.08-4.23 [p = 0.03], respectively). Conclusions: B7-H1 is expressed in a substantial proportion of malignant pleural mesotheliomas and is associated with poor survival. Almost all malignant pleural mesotheliomas with sarcomatoid differentiation expressed B7-H1. The expression of B7-H1 may have important therapeutic implications for the management of malignant pleural mesothelioma.

KW - B7-H1

KW - Immunology

KW - Mesothelioma

KW - PD-L1

KW - Sarcomatoid

UR - http://www.scopus.com/inward/record.url?scp=84902522051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902522051&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000177

DO - 10.1097/JTO.0000000000000177

M3 - Article

C2 - 24926549

AN - SCOPUS:84902522051

VL - 9

SP - 1036

EP - 1040

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -